Foghorn Therapeutics (NASDAQ: FHTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.650 | ||||||
REV | 3.920M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Foghorn Therapeutics (NASDAQ: FHTX) through any online brokerage.
There are no as such competitors for Foghorn Therapeutics.
The latest price target for Foghorn Therapeutics (NASDAQ: FHTX) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 21.00 expecting FHTX to rise to within 12 months (a possible 50.86% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Foghorn Therapeutics (NASDAQ: FHTX) is $13.92 last updated June 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Foghorn Therapeutics.
Foghorn Therapeutics’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Foghorn Therapeutics.
Foghorn Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.